Structure of Human Tyrosinase Related Protein 1 Reveals a Binuclear Zinc Active Site Important for Melanogenesis

Xuelei Lai, Harry J. Wichers, Montserrat Soler-Lopez,* and Bauke W. Dijkstra*

Abstract: Tyrosinase-related protein 1 (TYRP1) is one of three tyrosinase-like glycoenzymes in human melanocytes that are key to the production of melanin, the compound responsible for the pigmentation of skin, eye, and hair. Difficulties with producing these enzymes in pure form have hampered the understanding of their activity and the effect of mutations that cause albinism and pigmentation disorders. Herein we show that the typical tyrosinase-like subdomain of TYRP1 contains two zinc ions in the active site instead of copper ions as found in tyrosinases, which explains why TYRP1 does not exhibit tyrosinase redox activity. In addition, the structures reveal for the first time that the Cys-rich subdomain, which is unique to vertebrate melanogenic proteins, has an epidermal growth factor-like fold and is tightly associated with the tyrosinase subdomain. Our structures suggest that most albinism-related mutations of TYRP1 affect its stability or activity.

In humans, three enzymes are involved in the biosynthesis of melanin (Figure S1 in the Supporting Information), the primary determinant of the color of the skin, hair and iris of the eye.[1] Tyrosinase (TYR) is the critical and rate-limiting enzyme; it catalyzes the hydroxylation and subsequent oxidation of tyrosine. Tyrosinase-related protein 2 (TYRP2) has been suggested to catalyze the oxidation of 5,6-dihydroxyindole-2-carboxylic acid (DHICA) in mice,[3] although this activity has been challenged in humans.[4] All three enzymes are metal-containing glycoproteins localized in melanosomes where melanin synthesis takes place. They share approximately 40% amino acid sequence identity and contain four conserved regions: an N-terminal signal peptide, an intramelanosomal domain, a single transmembrane α-helix, and a small, flexible C-terminal cytoplasmic domain (Figure 1 A). The intramelanosomal domain contains a Cys-rich subdomain, unique to mammalian tyrosinases, and a tyrosinase-like subdomain with a binuclear metal-ion-binding sequence motif. Mutations in the TYR or TYRP1 genes result in oculocutaneous albinism (OCA), a group of autosomal recessive disorders characterized by reduced production of melanin in skin, hair, and eyes, with OCA3 resulting from TYRP1 mutations. In addition, TYR and TYRP1 variants are significantly associated with risk of melanoma,[5] a malignant tumor of melanocytes that, because of its aggressive nature, causes the majority of deaths related to skin cancer.[6] Inhibition of melanogenesis may be an efficient therapeutic strategy, as evidenced by phase 1 clinical trials with a recombinant human monoclonal antibody against TYRP1.[7]

Although we recently succeeded in the recombinant production of intramelanosomal human TYR,[8] its crystallization was not suitable for structure determination. Herein we report the crystal structure of intramelanosomal human TYRP1 and in complex with tyrosinase substrates and inhibitors, which reveal for the first time the structure of a mammalian tyrosinase family member. We show that the active site contains two zinc ions, rather than copper ions as in tyrosinases, which makes it unlikely that human TYRP1 is a redox enzyme, as had been assumed for the last three decades.

The 2.35 Å resolution crystal structure of intramelanosomal TYRP1 (Figure 1 B, Table S1) reveals a compact globular shape, with tight interactions between the Cys-rich and tyrosinase subdomains. Furthermore, all six Asn N-glycosylation motifs bear glycans (96, 104, 181, 304, 350, and 385) (Figure 1 B and Figure S2). The tyrosinase-like subdomain (residues 127–477) has the typical tyrosinase fold, consisting of a four-helix bundle (α3, α4, α8, and α9) connected by long loops. It is most similar to the bacterial Bacillus megaterium tyrosinase (BmTYR, PDB entry 3NM8),[9] with 32% sequence identity and an rmsd of 1.6 Å for 263 aligned amino acids. The most conspicuous differences are three long insertions that cluster together at one side of the tyrosinase-like subdomain (Figure 2; residues 155–182, 199–204, and 291–300). These loops extend away from the entrance to the active site, and interact with the Cys-rich subdomain. Two disulfide bonds (C258–C261 and C290–C303) stabilize the tyrosinase subdomain (disulfide bonds 6 and 7 in Figure S2).

The core of the Cys-rich subdomain (residues 25–126) has an epidermal growth factor (EGF)-like fold (SCOP family g.3.11.1) similar to the structure of the human epidermal
growth factor (Figure S3), formed by two pairs of short antiparallel β-strands (β1/β2 (residues 62–66/98–102) and β4/β5 (116–118/124–126; Figure 1B) from which long loops emerge. They are stabilized by disulfide bonds that follow the [C{1–C{3, C{2–C{4, C{5–C{6}] signature pattern of EGF-like structures, corresponding to cysteine residues 42–65, 56–99, 101–110. The subdomain associates with the tyrosinase-like subdomain via its N-terminus and the long 67–97 loop extending from the core. The subdomain is located far from the active site, at the opposite side of the molecule (Figure 1B), making a direct effect on the activity of TYRP1 unlikely. Although the Cys-rich subdomain has been suggested to be involved in oligomerization, we did not find evidence for this, since purified intramelanosomal domains of both TYRP1 and TYR elute as monomers on size-exclusion chromatography (Figure S4A), and co-elution of TYRP1 and TYR did neither produce a heterodimer (Figure S4B).

TYRP1 has a binuclear metal-binding site that resembles the classical type-3 binuclear copper-binding site of hemocyanins and tyrosinases (Figure 3), but the nature of the bound metal ions has been unclear.[12] Using X-ray fluorescence, we found that TYRP1 crystals contained zinc, while TYR crystals contained copper (Figure S5). The presence of zinc in TYRP1 was further confirmed by X-ray anomalous dispersion data collected at the zinc absorption edge, which showed that the TYRP1 zinc ions occupy the positions of copper ions in tyrosinases (Figure S6 and Table S1). Both zinc ions in the active site are bound with an early planar trigonal geometry, slightly out of the plane defined by the Nζ atoms of their ligands. The distance between the ZnA and ZnB ions (Figure 3) is $3.5 \pm 0.1$ Å. A bridging water molecule or...
hydroxide ion can be modeled with a distance of 2.1 ± 0.1 Å to the two zinc ions (Figure 3A and Figure S7A). Although we carried out repeated productions of TYRP1 and TYR samples under identical cell culture conditions and in the absence of external sources of zinc or copper ions in the media, the two proteins consistently contain different ions, unambiguously proving that TYR is a copper-binding enzyme while TYRP1 is a zinc-binding enzyme.

Generally, it has been assumed that TYRP1 is a DHICA oxidase. Yet, human TYRP1 was found to be devoid of DHICA activity, and also in our studies the intramelanosomal domain of TYRP1 did not display any DHICA activity nor tyrosine hydroxylase or l-DOPA oxidase activity (Figure 4). The nature of the metal ions in the active site is partly responsible for these differences in activity, since exchanging the Zn$^{2+}$/Cu$^{2+}$ cofactors of TYRP1/TYR for Cu$^{2+}$/Zn$^{2+}$ conferred TYR-level DHICA oxidase activity to TYRP1, but no significant l-DOPA oxidase and tyrosine hydroxylase activities. Only a prolonged (up to 160 min) on-plate tyrosinase activity assay with TYRP1-Cu did show some low tyrosinase activity (Figure 4D). In contrast, TYR-Zn had almost no activity, with the residual activity likely resulting from incomplete removal of the copper ions. Amino acid substitutions in the active site affect the activity profile only to a minor extent. A triple mutant, which had the three non-identical residues replaced by the corresponding ones of TYR (Y362F/R374S/T391V; TYRP1-3M), had similar activities as native TYRP1, both in the Zn- and Cu-substituted forms. Thus, our results suggest that it is unlikely that TYRP1 is a redox enzyme.

TYRP1 binds typical tyrosinase substrates and inhibitors (Figure 5, Table S1). Importantly, l-tyrosine and the l-DOPA analogue l-mimosine do not directly interact with the zinc ions, but their aromatic hydroxy and keto-groups are hydrogen-bonded to the water molecule bridging the two zinc ions (Figure S7B). Additional interactions include offset aromatic stacking interactions with His381, and hydrogen bonding interactions of their carboxylate group with Arg374 and Ser394 (Figure 5 A,B). The electron density of l-mimosine is better defined than that of l-tyrosine, suggesting that the interactions of the l-hydroxy group increase the binding affinity of mimose. In contrast, the metal chelator tropolone does have direct interactions with the ZnA ion (Figure 5C). Interestingly, ZnA has shifted by 1.5 Å towards tropolone compared to native TYRP1, indicating that the metal ion site is somewhat flexible. The skin-whitening agent kojic acid binds with its ring hydroxy and keto groups at approximately 3 Å from the zinc ions, which is too far for good coordination (Figure 5D). Interestingly, the amino acid differences between the active sites of TYRP1 and TYR do not affect the binding modes of these compounds, as shown by crystal structures of the TYRP1-3M mutant (see above) with/without bound l-mimosine, tropolone and kojic acid (Figure S8, Table S1). Despite removal of hydrogen-bonding interactions by the mutations, the compounds bind in a similar conformation as in native TYRP1. Apparently, the stacking interaction with His381 and the hydrogen bonds of aromatic keto- and hydroxy groups are sufficient for binding. This finding implies that recognition of the substrate’s carboxylate group is not essential and that, in addition to DHICA, TYRP1 may also be active on 5,6-dihydroxyindole (DHI) (Figure S1).

Fifteen OCA3-related mutations in the TYRI gene have so far been found, including 8 point mutations (C30R, R93C, H215Y, T253M, C290Y, R356Q, M452V, and P513R; Figure S9). Most of these residues contribute to the stability. The C30–C41 disulfide bond attaches helix α1 to the core of the Cys-rich subdomain, the C290–C303 disulfide bond stabilizes the 290–303 loop, and R356 is part of an extensive buried hydrogen-bonding network. H215 is a ZnA ligand, and replacement by Tyr may reduce the enzyme’s zinc-binding affinity and activity. T253M and M452V are missense mutations found in Caucasian patients that are yet to be confirmed as pathological mutations.

T253 is located on a surface loop, far away from the active site, and the introduction of a large apolar methionine at this position may lead to local unfolding and/or aggregation. M452 is located in the interface between the Cys-rich and tyrosinase-like subdomains. Replacement by Val may reduce part of its hydrophobic interactions,
which may have a (probably minor) effect on the stability of the enzyme. The R93C substitution causes blond hair in normally black-haired Melanesian individuals. R93 is near a cluster of four disulphide bonds in the Cys-rich subdomain (Figure S9), and replacement by a cysteine could interfere with correct disulfide bond formation or even correct folding. Finally, the P513R mutation is in the cytosolic tail domain, which is critical for targeting melanogenic proteins to the melanosomal membrane. The P513R replacement may thus interfere with translocation of TYRP1 to the melanosomal membrane.

In summary, the crystal structure of intramelanosomal human tyrosinase-related protein 1 (TYRP1) has revealed for the first time the structure of a mammalian tyrosinase family member. We provide compelling evidence for the presence of two zinc ions in the active site, which makes it unlikely that human TYRP1 is a redox enzyme, in contrast to what has been assumed for the last three decades. Which reaction TYRP1 does catalyze is unclear at this moment, although the effect of mutations in the TYRP1 gene suggest the utmost importance of TYRP1 for the biosynthesis of melanin.

Acknowledgements

We thank ESRF beamline scientists D. de Sanctis (ID29), A. Popov (ID23-1), and M. Bowler (MASSIF-1) for assistance during data collection, and F. Garzoni (Eukaryotic Expression Platform at EMBL Grenoble) for help with protein expression in insect cells. The Structural Biology Group at the ESRF and the Groningen Biomolecular Sciences and Biotechnology Institute (University of Groningen) supported this work.

Conflict of interest

The authors declare no conflict of interest.

Keywords: albinism · human tyrosinase · melanogenesis · structure elucidation · zinc–copper enzymes

How to cite: Angew. Chem. Int. Ed. 2017, 56, 9812–9815

Angew. Chem. 2017, 129, 9944–9947

[1] J. L. Rees. Annu. Rev. Genet. 2003, 37, 67–90.
[2] Y. Yamaguchi, V. J. Hearing, Cold Spring Harbor Perspect. Med. 2014, 4, a017046.
[3] T. Kobayashi, K. Urabe, A. Winder, C. Jiménez-Cervantes, G. Imokawa, T. Brewington, F. Solano, J. C. García-Borrón, V. J. Hearing, EMBO J. 1994, 13, 5818–5825.
[4] R. E. Boissy, C. Sakai, H. Zhao, T. Kobayashi, V. J. Hearing, Exp. Dermatol. 1998, 7, 198–204.
[5] G. Ghanem, J. Fabrice, Mol. Oncol. 2011, 5, 150–155.
[6] R. L. Siegel, K. D. Miller, A. Jemal, Ca-Cancer J. Clin. 2016, 66, 7–30.
[7] D. N. Khalil, M. A. Postow, N. Ibrahim, D. L. Ludwig, J. Cosaert, S. R. Pambhampati, S. Tang, D. Grebennik, J. S. W. Kauh, H. J. Lenz, et al., Clin. Cancer Res. 2016, 22, 5204–5210.
[8] X. Lai, M. Soler-Lopez, H. J. Wickers, B. W. Dijkstra, PLoS One 2016, 11, e0161697.
[9] M. Sendovski, M. Kanteev, V. S. Ben-Yosef, N. Adir, A. Fishman, J. Mol. Biol. 2011, 405, 227–237.
[10] H. S. Lu, J. J. Chai, M. Li, B. R. Huang, C. H. He, R. C. Bi, J. Biol. Chem. 2001, 276, 34913–34917.
[11] I. J. Jackson, D. M. Chambers, K. Tsukamoto, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, V. Hearing, EMBO J. 1992, 11, 527–535.
[12] M. Furumura, F. Solano, N. Matsunaga, C. Sakai, R. A. Spritz, V. J. Hearing, Biochim. Biophys. Res. Commun. 1998, 242, 579–585.
[13] R. Sarangarajan, R. E. Boissy, Pigment Cell Res. 2001, 14, 437–444.
[14] B. Deri, M. Kanteev, M. Goldfeder, D. Lecina, V. Guallar, N. Adir, A. Fishman, Sci. Rep. 2016, 6, 34993.
[15] P. D. Stenson, M. Mort, E. V. Ball, K. Howells, A. D. Phillips, N. S. Thomas, D. N. Cooper, Genome Med. 2009, 1, 13.
[16] S. M. Hutton, A.-B. Olofsson, Invest. Ophthalmol. Visual Sci. 2008, 49, 868–872.
[17] E. E. Kenny, N. J. Timpson, M. Sikora, M.-C. Yee, A. Moreno-Estrada, C. Eng, S. Huntsman, E. G. Burchard, M. Stoneking, C. D. Bustamante, et al., Science 2012, 336, 554–554.
[18] P. A. Calvo, D. W. Frank, B. M. Bieler, J. F. Berson, M. S. Marks, J. Biol. Chem. 1999, 274, 12780–12789.